
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
A recap of the FDA submissions and regulatory decisions in urology from December 2025.
Welcome to Urology Times’® monthly FDA update! The year wrapped up with a flurry of regulatory approvals across prostate cancer, benign prostatic hyperplasia (BPH), and other benign conditions. Notable advances in December included clearance of the Hugo robotic system for urologic procedures as well as approvals for the ProVee and Zenflow Systems in BPH.







